Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study.

Lüftner, D., Welslau, M., Liersch, R., Deryal, M., Brucker, C., Rauh, J., Welt, A., Zaiss, M., Houet, L., Vannier, C., Potthoff, K., Marschner, N., 2020.

Oncol Res Treat 43 (suppl 1)(272), 14.